OncoBone Therapeutics presents new data about its lead asset OBP-004, a novel small molecule dual inhibitor of CDK9/13, in a poster presentation in the American Association of Cancer Research (AACR) Annual Meeting in Chicago, IL, USA on April 25 – 30, 2025.
Tiina Kähkönen, CSO of OncoBone Therapeutics says: “We are excited to present our new data about OBP-004 to the scientific community in AACR. OBP-004 is a highly potent and selective dual inhibitor of CDK9/13. Our data demonstrates that dual inhibition of CDK9/13 is needed for the observed strong anti-metastatic effects, especially on bone metastases.”
The poster presentation will be held on Monday, April 28, 2025 at 2 – 5 pm in poster board 13 in section 20. The poster presentation is available as a pdf file after the AACR event. Please reach out to info@oncobone.com for further information.